Vir Biotechnology, Inc. (VIR)
Largest Insider Buys in Sector
VIR Stock Price History Chart
VIR Stock Performance
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Insider Activity of Vir Biotechnology, Inc.
Over the last 12 months, insiders at Vir Biotechnology, Inc. have bought $0 and sold $2.03M worth of Vir Biotechnology, Inc. stock.
On average, over the past 5 years, insiders at Vir Biotechnology, Inc. have bought $82,446 and sold $55.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $56,816 was made by Sigal Charles Elliott (director) on 2023‑03‑01.
List of Insider Buy and Sell Transactions, Vir Biotechnology, Inc.
| 2025-01-08 | Sale | director | 10,960 0.008% | $12.52 | $137,219 | -0.32% | ||
| 2024-12-02 | Sale | EVP and General Counsel | 76 <0.0001% | $8.22 | $625 | -7.98% | ||
| 2024-11-06 | Sale | EVP and General Counsel | 4,397 0.0032% | $10.11 | $44,454 | -23.11% | ||
| 2024-11-05 | Sale | EVP and General Counsel | 2,347 0.0017% | $9.47 | $22,225 | +7.13% | ||
| 2024-11-01 | Sale | EVP and General Counsel | 1,403 0.0008% | $7.20 | $10,107 | -15.12% | ||
| 2024-09-09 | Sale | director | 12,190 0.0089% | $7.80 | $95,032 | -1.79% | ||
| 2024-06-11 | Sale | director | 4,000 0.003% | $10.95 | $43,789 | -25.07% | ||
| 2024-04-03 | Sale | Chief Executive Officer | 72,995 0.0528% | $9.46 | $690,365 | -13.11% | ||
| 2024-04-01 | Sale | EVP & Chief Technology Officer | 2,711 0.002% | $10.05 | $27,251 | -17.01% | ||
| 2024-03-27 | Sale | EVP & Chief Financial Officer | 6,008 0.0044% | $9.89 | $59,404 | -15.64% | ||
| 2024-02-26 | Sale | director | 17,722 0.0129% | $11.65 | $206,522 | -26.13% | ||
| 2024-02-22 | Sale | EVP & Chief Medical Officer | 14,568 0.0106% | $10.05 | $146,344 | -13.79% | ||
| 2024-02-22 | Sale | EVP & Chief Technology Officer | 12,296 0.0089% | $10.05 | $123,521 | -13.79% | ||
| 2024-02-22 | Sale | director | 10,028 0.0073% | $10.05 | $100,737 | -13.79% | ||
| 2024-02-20 | Sale | director | 16,872 0.0126% | $10.22 | $172,385 | -12.51% | ||
| 2024-02-16 | Sale | EVP & Chief Medical Officer | 3,321 0.0025% | $10.24 | $34,006 | -12.68% | ||
| 2024-02-16 | Sale | director | 10,878 0.0081% | $10.24 | $111,386 | -12.68% | ||
| 2023-06-30 | Sale | 10 percent owner | 700 0.0005% | $25.11 | $17,577 | -59.52% | ||
| 2023-06-30 | Sale | director | 18,000 0.0136% | $24.66 | $443,916 | -59.52% | ||
| 2023-06-29 | Sale | 10 percent owner | 89,942 0.0679% | $25.18 | $2.26M | -60.15% |
Insider Historical Profitability
| SATO VICKI L | director | 1312391 0.9529% | $12.18 | 0 | 24 | |
| De Backer Marianne | Chief Executive Officer | 678457 0.4926% | $12.18 | 0 | 1 | |
| Pang Phillip | EVP & Chief Medical Officer | 250111 0.1816% | $12.18 | 0 | 38 | |
| HANLY ANN M. | EVP & Chief Technology Officer | 132069 0.0959% | $12.18 | 1 | 5 | <0.0001% |
| SCANGOS GEORGE A | director | 112989 0.082% | $12.18 | 0 | 10 | |
| Lee Sung | EVP & Chief Financial Officer | 100492 0.073% | $12.18 | 0 | 1 | |
| de Verneuil Vanina | EVP and General Counsel | 56973 0.0414% | $12.18 | 0 | 4 | |
| Ramasastry Saira | director | 14619 0.0106% | $12.18 | 0 | 5 | |
| Napolitano Janet | director | 11616 0.0084% | $12.18 | 0 | 3 | |
| SOFTBANK VISION FUND (AIV M1) L.P. | 22094080 16.0428% | $12.18 | 0 | 1 | ||
| SVF Endurance (Cayman) Ltd | 10 percent owner | 16684041 12.1145% | $12.18 | 1 | 80 | +115.34% |
| Alaska Permanent Fund Corp | 10 percent owner | 5555556 4.034% | $12.18 | 1 | 0 | +115.34% |
| Temasek Holdings (Private) Ltd | 10 percent owner | 5499999 3.9936% | $12.18 | 1 | 0 | +115.34% |
| Abu Dhabi Investment Authority | 3666666 2.6624% | $12.18 | 1 | 0 | +115.34% | |
| NELSEN ROBERT | 1000000 0.7261% | $12.18 | 1 | 0 | +115.34% | |
| Burow Kristina | director | 1000000 0.7261% | $12.18 | 1 | 0 | +115.34% |
| ARCH Venture Partners IX, LLC | 10 percent owner | 1000000 0.7261% | $12.18 | 1 | 0 | +115.34% |
| Horn Howard | CFO | 230712 0.1675% | $12.18 | 0 | 9 | |
| Virgin Herbert | EVP, Research & CSO | 175407 0.1274% | $12.18 | 0 | 58 | |
| Friedl-Naderer Johanna | EVP & Chief Operating Officer | 148518 0.1078% | $12.18 | 0 | 1 | |
| Rice Steven J. | Chief Administrative Officer | 106840 0.0776% | $12.18 | 0 | 7 | |
| PATRICK DONALD A | director | 52000 0.0378% | $12.18 | 1 | 0 | |
| MORE ROBERT J | director | 36030 0.0262% | $12.18 | 0 | 7 | |
| Sigal Charles Elliott | director | 10000 0.0073% | $12.18 | 4 | 0 | <0.0001% |
| Parrish Jay | Chief Business Officer | 9260 0.0067% | $12.18 | 0 | 12 | |
| WILBURN JAMES R | director | 3295 0.0024% | $12.18 | 0 | 1 |
Institutional Investor Ownership
| SoftBank Investment Advisers | $169.01M | 12.26 | 16.68M | 0% | +$0 | 1.67 | |
| BlackRock | $167.79M | 12.17 | 16.56M | -1.78% | -$3.05M | <0.01 | |
| The Vanguard Group | $125.36M | 9.1 | 12.38M | +0.64% | +$792,328.08 | <0.01 | |
| State Street | $71.6M | 5.2 | 7.07M | +2.25% | +$1.58M | <0.01 | |
| Baillie Gifford Co | $39.98M | 2.9 | 3.95M | -0.47% | -$187,242.92 | 0.03 | |
| Citadel Advisors LLC | $34.52M | 2.51 | 3.41M | +12.18% | +$3.75M | 0.02 | |
| Morgan Stanley | $23.7M | 1.72 | 2.34M | +10.02% | +$2.16M | <0.01 | |
| Geode Capital Management | $19.75M | 1.43 | 1.95M | +3.33% | +$636,184.14 | <0.01 | |
| Bill & Melinda Gates Foundation | $15.79M | 1.15 | 1.56M | 0% | +$0 | 18.82 | |
| Renaissance Technologies | $13.74M | 1 | 1.36M | +4.75% | +$622,981.71 | 0.02 | |
| Bridgeway Capital Management | $12.85M | 0.93 | 1.27M | -5.59% | -$761,370.82 | 0.18 | |
| Bank of America | $11.51M | 0.84 | 1.14M | +645.91% | +$9.97M | <0.01 | |
| Citigroup | $11.39M | 0.83 | 1.12M | +445.93% | +$9.31M | 0.01 | |
| Barclays | $10.28M | 0.75 | 1.01M | +128.18% | +$5.77M | 0.01 | |
| Goldman Sachs | $9.14M | 0.66 | 902,342 | +56.18% | +$3.29M | <0.01 | |
| Northern Trust | $8.7M | 0.63 | 858,591 | -8.4% | -$797,362.61 | <0.01 | |
| Charles Schwab | $8.4M | 0.61 | 829,311 | +10.12% | +$772,290.99 | <0.01 | |
| BNY Mellon | $8.17M | 0.59 | 806,929 | +11.93% | +$871,494.06 | <0.01 | |
| Voloridge Investment Management, LLC | $7.13M | 0.52 | 703,528 | +27.04% | +$1.52M | 0.03 | |
| D. E. Shaw & Co. | $6.55M | 0.48 | 646,254 | -15.98% | -$1.24M | 0.01 | |
| Millennium Management LLC | $6.5M | 0.47 | 641,327 | +56.4% | +$2.34M | <0.01 | |
| OrbiMed | $6.48M | 0.47 | 640,000 | +533.66% | +$5.46M | 0.05 | |
| Dimensional Fund Advisors | $5.87M | 0.43 | 579,126 | +23.66% | +$1.12M | <0.01 | |
| UBS | $4.72M | 0.34 | 466,208 | -11.4% | -$607,516.35 | <0.01 | |
| JPMorgan Chase | $4.69M | 0.34 | 463,247 | +104.48% | +$2.4M | <0.0001 | |
| Empowered Funds Llc | $4.64M | 0.34 | 458,044 | +8.18% | +$350,903.22 | 0.08 | |
| Invesco | $4.55M | 0.33 | 448,960 | +54.8% | +$1.61M | <0.01 | |
| Rafferty Asset Management Llc | $4.45M | 0.32 | 439,323 | +10.11% | +$408,775.89 | 0.01 | |
| Ameriprise Financial | $3.27M | 0.24 | 322,576 | +3.14% | +$99,517.12 | <0.01 | |
| Jacobs Levy Equity Management | $3.14M | 0.23 | 310,091 | +5.66% | +$168,309.96 | 0.01 | |
| Hudson Bay Capital Management LP | $2.89M | 0.21 | 285,000 | -1.72% | -$50,650.00 | 0.02 | |
| Ci Private Wealth Llc | $2.73M | 0.2 | 269,912 | +0.98% | +$26,672.29 | <0.01 | |
| Capital International Investors | $2.62M | 0.19 | 258,400 | 0% | +$0 | <0.01 | |
| Legal & General | $2.55M | 0.19 | 251,289 | +2.75% | +$68,093.85 | <0.01 | |
| Nordea Investment Management Ab | $2.41M | 0.17 | 235,664 | +58.72% | +$891,081.77 | <0.01 | |
| RhumbLine Advisers | $2.32M | 0.17 | 228,687 | -16.98% | -$473,785.26 | <0.01 | |
| Nuveen | $2.11M | 0.15 | 208,300 | 0% | +$0 | <0.01 | |
| Qube Research & Technologies | $1.89M | 0.14 | 186,843 | -14.45% | -$319,561.05 | <0.01 | |
| Swiss National Bank | $1.88M | 0.14 | 185,200 | 0% | +$0 | <0.01 | |
| Public Sector Pension Investment Board | $1.81M | 0.13 | 178,659 | 0% | +$0 | 0.01 | |
| Walleye Capital | $1.75M | 0.13 | 172,656 | -6.08% | -$113,131.82 | 0.01 | |
| State of Alaska Department of Revenue | $1.54M | 0.11 | 152,447 | -0.34% | -$5,246.36 | 0.02 | |
| American Century Investments | $1.51M | 0.11 | 149,268 | +50.21% | +$505,456.66 | <0.01 | |
| Prudential Financial | $1.45M | 0.11 | 142,729 | -69.34% | -$3.27M | <0.01 | |
| AllianceBernstein | $1.11M | 0.08 | 109,620 | -96.06% | -$27.06M | <0.0001 | |
| ROYCE & ASSOCIATES INC | $1.04M | 0.08 | 102,900 | 0% | +$0 | 0.01 | |
| Franklin Templeton Investments | $1.04M | 0.08 | 102,894 | +593.4% | +$891,996.11 | <0.0001 | |
| Duality Advisers Lp | $1.03M | 0.08 | 101,479 | +6.65% | +$64,133.01 | 0.1 | |
| Credit Suisse | $1.02M | 0.07 | 100,443 | -21.39% | -$276,842.61 | <0.01 | |
| Jane Street Capital | $1.02M | 0.07 | 100,510 | +37.11% | +$275,576.44 | <0.01 |